E
Ernst A. de Bruijn
Researcher at Katholieke Universiteit Leuven
Publications - 64
Citations - 3944
Ernst A. de Bruijn is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Melphalan & Isolated lung perfusion. The author has an hindex of 24, co-authored 64 publications receiving 3690 citations. Previous affiliations of Ernst A. de Bruijn include The Catholic University of America & Catholic University of Leuven.
Papers
More filters
Journal ArticleDOI
Vascular Endothelial Growth Factor and Angiogenesis
Ann Hoeben,Bart Landuyt,Martin Highley,Hans Wildiers,Allan T. van Oosterom,Ernst A. de Bruijn +5 more
TL;DR: The role of V EGF in physiological and pathological processes is reviewed and how modulation of VEGF expression creates new therapeutic possibilities is discussed.
Journal ArticleDOI
Interaction of Imatinib with Human Organic Ion Carriers
Shuiying Hu,Ryan M. Franke,Kelly K. Filipski,Kelly K. Filipski,Chaoxin Hu,Shelley Orwick,Ernst A. de Bruijn,Herman Burger,Sharyn D. Baker,Alex Sparreboom,Alex Sparreboom +10 more
TL;DR: This study suggests that SLC22A1 expression is a composite surrogate for expression of various transporters relevant to imatinib IUR, which provides a mechanistic explanation for previous studies that have linked SLC 22A1 with the antitumor activity ofImatinib.
Journal ArticleDOI
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Herman Burger,Hans van Tol,Mariël Brok,Erik A.C. Wiemer,Ernst A. de Bruijn,Gunther Guetens,Gert De Boeck,Alex Sparreboom,Jaap Verweij,Kees Nooter +9 more
TL;DR: It is found that continuous exposure (up to 100 days) with imatinib specifically upregulates the expression of ABCG2 and ABCB1 and this might be anticipated that drug-induced upregulation of these intestinal pumps could reduce the oral bioavailability of Imatinib.
Journal ArticleDOI
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
Erin R. Gardner,Herman Burger,Ron H.N. van Schaik,Allan T. van Oosterom,Ernst A. de Bruijn,Gunther Guetens,Hans Prenen,Floris A. de Jong,Sharyn D. Baker,Susan E. Bates,William D. Figg,Jaap Verweij,Alex Sparreboom,Kees Nooter +13 more
TL;DR: The objective was to explore the relationships between imatinib pharmacokinetics and 9 allelic variants in 7 genes coding for adenosine triphosphate‐binding cassette transporters and enzymes of putative relevance forImatinib.
Journal ArticleDOI
Pharmacology of Anticancer Drugs in the Elderly Population
TL;DR: The factors that can influence the pharmacokinetics of anticancer drugs frequently used in the elderly, and the clinical or biochemical parameters that form the basis for dose adjustments with age are elucidated.